cancer risk with semaglutide (Ozempic) carries FDA warnings for thyroid C-cell tumors based on rodent studies, emerging human data showing higher thyroid in early users. Over 2,900 lawsuits allege inadequate warnings for GLP-1 Side Effects and Cancer

This makes topical serums well-suited for cosmetic use and a potentially valuable part of many professional skincare and hair growth products

Pharmacies are not allowed to make these drugs under the old shortage rules anymore

The more frequent injection site reactions with exenatide once weekly (22%) compared with semaglutide (1.2%) in SUSTAIN-3 could be a consequence of this ( The head-to-head studies within the SUSTAIN and PIONEER programs allow some comparison of the adverse effect profile ( Table 2 )

Tesofensine is an oral small-molecule triple monoamine reuptake inhibitor not a peptide developed for weight loss and studied in Phase 2 trials as a once-daily 0.5 mg capsule

Although the availability of doses has increased since demand for weight loss medications is still at a high in the United States